Rothschild Investment LLC Has $402,000 Holdings in GSK plc (NYSE:GSK)

Rothschild Investment LLC cut its position in GSK plc (NYSE:GSK) by 30.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 11,876 shares of the pharmaceutical company’s stock after selling 5,140 shares during the quarter. Rothschild Investment LLC’s holdings in GSK were worth $402,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of GSK. Sunbelt Securities Inc. grew its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. Mesirow Financial Investment Management Inc. grew its position in GSK by 2.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after purchasing an additional 323 shares during the last quarter. Rehmann Capital Advisory Group grew its position in GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after purchasing an additional 332 shares during the last quarter. Bond & Devick Financial Network Inc. grew its position in GSK by 5.4% in the 3rd quarter. Bond & Devick Financial Network Inc. now owns 7,830 shares of the pharmaceutical company’s stock worth $320,000 after purchasing an additional 400 shares during the last quarter. Finally, Gladstone Institutional Advisory LLC grew its position in GSK by 3.4% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 12,221 shares of the pharmaceutical company’s stock worth $413,000 after buying an additional 407 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GSK shares. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and lowered their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

NYSE:GSK opened at $38.39 on Wednesday. The firm has a market cap of $79.56 billion, a PE ratio of 24.14, a price-to-earnings-growth ratio of 1.12 and a beta of 0.64. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The company’s 50-day moving average price is $34.76 and its two-hundred day moving average price is $37.30.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.10%. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is currently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.